Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Argenica Therapeutics Ltd ( (AU:AGN) ) has provided an update.
Argenica Therapeutics has announced significant findings from an AI-driven reanalysis of its Phase 2 trial, demonstrating the efficacy of its drug ARG-007 in improving outcomes for severe stroke patients. The analysis revealed that ARG-007 significantly improves functional outcomes and reduces infarct volumes in patients with severe strokes, presenting a substantial commercial opportunity and guiding the design of a precision medicine approach for future trials.
The most recent analyst rating on (AU:AGN) stock is a Buy with a A$0.63 price target. To see the full list of analyst forecasts on Argenica Therapeutics Ltd stock, see the AU:AGN Stock Forecast page.
More about Argenica Therapeutics Ltd
Argenica Therapeutics Limited is a biotechnology company focused on developing novel therapeutics aimed at reducing brain tissue death following a stroke. The company is involved in the research and development of neuroprotective drugs, with a particular focus on addressing the needs of patients with severe strokes.
Average Trading Volume: 280,896
Technical Sentiment Signal: Sell
Current Market Cap: A$32.11M
For an in-depth examination of AGN stock, go to TipRanks’ Overview page.